tirzepatide weight loss clinical trials Tirzepatide's Surmount-4 Trial Reveals Groundbreaking Results Tirzepatide trial shows additional 21.1%

Diabetes Care 42(9): 1724-1732

Alternative GLP-1 receptor agonists may be considered, as different formulations can have varying effects on gastric emptying and individual tolerance: Dulaglutide (Trulicity) another once-weekly injection with a potentially different side-effect profile Liraglutide (Victoza) a daily injection that some patients tolerate differently Exenatide available in both twice-daily and once-weekly formulations Whilst all GLP-1 receptor agonists share similar mechanisms of action and potential for gastrointestinal effects, individual patient responses can differ, and a trial of an alternative agent may prove beneficial

Also detoxifies the liver, kidneys and lymphatic system

GLP-1 mediated satiety is strong

Berthoud predicts something similar will happen with VIBES

Lower priced alternatives could expand access but also increase regulatory attention and safety debates